Quinone-Containing Conjugates for Synergistic Combinations

Publication ID: 24-11857638_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Quinone-Containing Conjugates for Synergistic Combinations,” Published Technical Disclosure No. 24-11857638_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857638_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,638.

Summary of the Inventive Concept

This inventive concept integrates quinone-containing conjugates with distinct technologies like AI, IoT, blockchain, and new materials to create a more powerful system for detecting and treating proliferative disorders.

Background and Problem Solved

The original patent disclosed quinone-containing conjugates for detecting and treating proliferative disorders, but it had limitations in terms of efficacy monitoring, supply chain management, and material properties. This new inventive concept addresses these limitations by synergistically combining the conjugates with AI, IoT, blockchain, and new materials.

Detailed Description of the Inventive Concept

The new system comprises a quinone-containing conjugate of formula (I) and an artificial intelligence module for analyzing the conjugate's binding affinity to tumor cells. Additionally, the system can be integrated with IoT-enabled devices for monitoring treatment efficacy, blockchain-based platforms for secure supply chain management, and composite materials comprising biodegradable polymers for targeted cancer therapy. The system can also utilize machine learning algorithms to predict the efficacy of the conjugate in treating proliferative disorders.

Novelty and Inventive Step

The new claims introduce novel synergistic combinations of quinone-containing conjugates with AI, IoT, blockchain, and new materials, which are non-obvious and provide significant improvements over the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different AI algorithms, IoT devices, or blockchain platforms. Variations of the composite material could include different biodegradable polymers or conjugate formulations.

Potential Commercial Applications and Market

The inventive concept has potential commercial applications in the fields of cancer therapy, diagnostics, and pharmaceuticals. The target market includes pharmaceutical companies, research institutions, and hospitals.

CPC Classifications

Section	Class	Group
A	A61	A61K47/6889
A	A61	A61K31/122
A	A61	A61K47/6891
A	A61	A61K49/0039
A	A61	A61K49/0043
A	A61	A61K49/0052
C	C07	C07D417/12
C	C07	C07K16/30
G	G01	G01N33/582

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical biotechnology, specifically antibody-drug conjugates (ADCs) for cancer treatment, involving organic chemistry, molecular biology, and drug delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level researcher with expertise in medicinal chemistry, protein engineering, and drug design, familiar with conjugate technologies, synthetic organic chemistry techniques, and interdisciplinary approaches to targeted therapeutics

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies and advanced materials with existing ADC platforms represents a predictable extension of known drug development strategies. The proposed combinations leverage standard techniques in AI, IoT, and materials science to enhance existing quinone-containing conjugate technologies. These modifications represent incremental improvements using well-established interdisciplinary approaches common in modern pharmaceutical research.

Obvious Combinations & Variations

Source Patent Element

Quinone-containing conjugates with selective cell binding moieties for targeting tumor cells

PTD Variation

Adding AI-powered binding affinity analysis to optimize conjugate targeting

Obviousness Reasoning

Using machine learning to analyze molecular interactions is a known technique in drug design, representing a predictable application of computational methods to existing conjugate technologies

Source Patent Element

Antibody drug conjugate with specific linker configurations

PTD Variation

Incorporating biodegradable polymer composites for improved drug delivery

Obviousness Reasoning

Modifying drug delivery systems with advanced materials is a standard approach in pharmaceutical engineering, with finite and predictable optimization strategies

Source Patent Element

Chemical conjugate with potential therapeutic applications

PTD Variation

Implementing blockchain tracking for supply chain management of specialized conjugates

Obviousness Reasoning

Applying blockchain to pharmaceutical tracking represents a known technique for improving transparency and traceability in drug development and distribution

Source Patent Element

Targeted molecular conjugates for proliferative disorder treatment

PTD Variation

Integrating IoT devices for real-time treatment efficacy monitoring

Obviousness Reasoning

Utilizing connected medical devices for treatment monitoring is a predictable technological progression in personalized medicine

Source Patent Element

Complex molecular conjugate with specific structural configurations

PTD Variation

Implementing machine learning algorithms to predict conjugate treatment efficacy

Obviousness Reasoning

Computational prediction of drug performance using structural analysis is a standard technique in modern pharmaceutical research with well-established methodological approaches

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed herein would be obvious to a person having ordinary skill in the art at the time of invention, as demonstrated by the predictable combination of known techniques from US Patent 11857638 with standard computational and materials science approaches. The proposed modifications represent incremental advancements that would be readily conceived by a skilled practitioner without requiring inventive insight beyond the existing technological landscape.

Original Patent Information

Patent Number	US 11,857,638
Title	Quinone-containing conjugates
Assignee(s)	Promega Corporation